NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy
Authored by
Abrar Choudhury, Martha A. Cady, Calixto-Hope G. Lucas, Hinda Najem, Joanna J. Phillips, Brisa Palikuqi, Naomi Zakimi, Tara Joseph, Janeth Ochoa Birrueta, William C. Chen, Nancy Ann Oberheim Bush, Shawn L. Hervey-Jumper, Ophir D. Klein, Christine M. Toedebusch, Craig M. Horbinski, Stephen T. Magill, Aparna Bhaduri, Arie Perry, Peter J. Dickinson, Amy B. Heimberger, Alan Ashworth, Elizabeth E. Crouch, and David R. Raleigh
- Posted
- Server
-
bioRxiv
Abstract
Summary
Meningiomas are the most common primary intracranial tumors1–3. Treatments for patients with meningiomas are limited to surgery and radiotherapy, and systemic therapies remain ineffective or experimental4,5. Resistance to radiotherapy is common in high-grade meningiomas6, and the cell types and signaling mechanisms driving meningioma tumorigenesis or resistance to radiotherapy are incompletely understood. Here we report NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy and find NOTCH3+ meningioma mural cells are conserved across meningiomas from humans, dogs, and mice. NOTCH3+ cells are restricted to the perivascular niche during meningeal development and homeostasis and in low-grade meningiomas but are expressed throughout high-grade meningiomas that are resistant to radiotherapy. Integrating single-cell transcriptomics with lineage tracing and imaging approaches across mouse genetic and xenograft models, we show NOTCH3 drives tumor initiating capacity, cell proliferation, angiogenesis, and resistance to radiotherapy to increase meningioma growth and reduce survival. An antibody stabilizing the extracellular negative regulatory region of NOTCH37,8blocks meningioma tumorigenesis and sensitizes meningiomas to radiotherapy, reducing tumor growth and improving survival in preclinical models. In summary, our results identify a conserved cell type and signaling mechanism that underlie meningioma tumorigenesis and resistance to radiotherapy, revealing a new therapeutic vulnerability to treat meningiomas that are resistant to standard interventions.
Read the preprint
